The registrational clinical trials and registry data of JAK inhibitors did not identify a difference in the risk of major adverse cardiovascular events, venous thromboembolism, malignancies or infections with a JAK inhibitor versus a biologic DMARD.
[Nature Reviews Rheumatology]
